Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-Le Initiated first ...

Launched Niktimvo in the U.S. in late January, in partnership with Incyte. Niktimvo is approved by the U.S. FDA for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least ...

AbbVie is jumping into the burgeoning obesity field, striking a license agreement with Gubra that is potentially worth more than $2 billion to the Danish drug-discovery and contract-research-services ...